Meeting
2022 ASCO Annual Meeting
Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.
Authors
Waleed Ikram
Mayo Clinic, Phoenix, AZ
Waleed Ikram , Syed Arsalan Ahmed Naqvi , Ammad Raina , Ezza Fatima , Rabbia Siddiqi , Mahnoor Islam , Noureen Asghar , Kaneez Zahra Rubab Khakwani , Ahsan Masood Khan , Syed A. Hussain , Alan Haruo Bryce , Irbaz Bin Riaz , Parminder Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Urothelial Cancer - Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4594)
DOI
10.1200/JCO.2022.40.16_suppl.4594
Abstract #
4594
Poster Bd #
85
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Prognostic significance of history of nonmuscle invasive bladder cancer in patients with muscle invasive bladder cancer treated with neoadjuvant chemotherapy followed by surgery.
First Author: Yongjune Lee
Poster
2023 ASCO Genitourinary Cancers Symposium
Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
First Author: Ahsan Ayaz
Poster
2023 ASCO Genitourinary Cancers Symposium
FDG PET-CT imaging in assessing interim response to neoadjuvant cisplatin-based chemotherapy (NAC) in muscle invasive bladder cancer (MIBC): A prospective study.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Genitourinary Cancers Symposium
A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.
First Author: Waleed Ikram